About AEterna Zentaris (NASDAQ:AEZS)
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing pharmaceutical therapies for treating oncology, endocrinology, and women's health. Its commercial product is the Macrilen, a ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a, a ghrelin receptor, which is used for endocrinology and oncology indications. The company has a license and assignment agreement with Strongbridge Ireland Limited for the development, manufacturing, registration, and commercialization of Macrilen in the United States and Canada. It also has a collaboration agreement with Sinopharm A-Think Pharmaceuticals Co., Ltd. for the development, manufacture, and commercialization of Zoptrex, which has completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer in the People's Republic of China. Aeterna Zentaris Inc. was founded in 1991 and is headquartered in Summerville, South Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:AEZS
CUSIPN/A
Phone843-900-3211
Debt
Debt-to-Equity RatioN/A
Current Ratio1.63%
Quick Ratio1.52%
Price-To-Earnings
Trailing P/E Ratio-1.19
Forward P/E Ratio-6.44
P/E GrowthN/A
Sales & Book Value
Annual Sales$920,000.00
Price / Sales28.77
Cash FlowN/A
Price / CashN/A
Book Value($0.17) per share
Price / Book-9.47
Profitability
EPS (Most Recent Fiscal Year)($1.35)
Net Income$-16,790,000.00
Net Margins-1,819.72%
Return on Equity-1,688.61%
Return on Assets-88.68%
Miscellaneous
Employees47
Outstanding Shares16,440,000
AEterna Zentaris (NASDAQ:AEZS) Frequently Asked Questions
What is AEterna Zentaris' stock symbol?
AEterna Zentaris trades on the NASDAQ under the ticker symbol "AEZS."
How were AEterna Zentaris' earnings last quarter?
AEterna Zentaris Inc. (NASDAQ:AEZS) released its quarterly earnings data on Wednesday, March, 28th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.13. The biopharmaceutical company earned $0.18 million during the quarter, compared to the consensus estimate of $0.14 million. AEterna Zentaris had a negative net margin of 1,819.72% and a negative return on equity of 1,688.61%. View AEterna Zentaris' Earnings History.
When is AEterna Zentaris' next earnings date?
What price target have analysts set for AEZS?
2 brokerages have issued 12-month target prices for AEterna Zentaris' stock. Their predictions range from $3.00 to $4.00. On average, they anticipate AEterna Zentaris' stock price to reach $3.50 in the next year. View Analyst Ratings for AEterna Zentaris.
Who are some of AEterna Zentaris' key competitors?
Some companies that are related to AEterna Zentaris include Cumberland Pharmaceuticals (CPIX), Forward Pharma (FWP), Columbia Laboratories (JNP), KalVista Pharmaceuticals (KALV), Sunesis Pharmaceuticals (SNSS), Galmed Pharmaceuticals (GLMD), Ophthotech (OPHT), Agile Therapeutics (AGRX), Aralez Pharmaceuticals (ARLZ), Flex Pharma (FLKS), Trillium Therapeutics (TRIL), BioLineRx (BLRX), Aptevo Therapeutics (APVO), KemPharm (KMPH) and Medicure (MCUJF).
Who are AEterna Zentaris' key executives?
AEterna Zentaris' management team includes the folowing people:
- Dr. Richard Sachse, Former Sr. VP, CSO & Chief Medical Officer
- Mr. Michael V. Ward, Chief Exec. Officer (Age 61)
- Mr. James Clavijo, Chief Financial Officer (Age 52)
- Mr. Paul Burroughs, Director of Communications
- Dr. Eckhard G. Guenther, VP of Alliance Management
Has AEterna Zentaris been receiving favorable news coverage?
Headlines about AEZS stock have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AEterna Zentaris earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 45.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.
How do I buy shares of AEterna Zentaris?
Shares of AEZS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AEterna Zentaris' stock price today?
One share of AEZS stock can currently be purchased for approximately $1.61.
How big of a company is AEterna Zentaris?
AEterna Zentaris has a market capitalization of $25.65 million and generates $920,000.00 in revenue each year. The biopharmaceutical company earns $-16,790,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. AEterna Zentaris employs 47 workers across the globe.
How can I contact AEterna Zentaris?
AEterna Zentaris' mailing address is 1 PLACE VILLE MARIE SUITE 2500, MONTREAL A8, H3B 1R1. The biopharmaceutical company can be reached via phone at 843-900-3211 or via email at [email protected]
MarketBeat Community Rating for AEterna Zentaris (AEZS)
MarketBeat's community ratings are surveys of what our community members think about AEterna Zentaris and other stocks. Vote "Outperform" if you believe AEZS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AEZS will underperform the S&P 500 over the long term. You may vote once every thirty days.
AEterna Zentaris (NASDAQ:AEZS) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for AEterna Zentaris in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 117.39%. The high price target for AEZS is $4.00 and the low price target for AEZS is $3.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.50 | $3.50 | $3.50 | $4.3333 |
| Price Target Upside: | 117.39% upside | 38.88% upside | 38.88% upside | 150.48% upside |
AEterna Zentaris (NASDAQ:AEZS) Consensus Price Target History
AEterna Zentaris (NASDAQ:AEZS) Analyst Ratings History
Show:
(Data available from 4/23/2016 forward)
AEterna Zentaris (NASDAQ:AEZS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
AEterna Zentaris (NASDAQ AEZS) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 1.91%
AEterna Zentaris (NASDAQ AEZS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
AEterna Zentaris (NASDAQ AEZS) News Headlines
| Source: |
|
AEterna Zentaris (NASDAQ:AEZS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
AEterna Zentaris (NASDAQ:AEZS) Income Statement, Balance Sheet and Cash Flow Statement
AEterna Zentaris (NASDAQ AEZS) Stock Chart for Monday, April, 23, 2018
Loading chart…
